Teledyne Technologies Incorporated (NYSE: TDY) has entered into a definitive agreement to acquire Varex Imaging Corporation (NASDAQ: VREX) for approximately $18.90 per share in cash, representing a total transaction value of approximately $1.1 billion. The transaction is expected to close in early 2027, subject to regulatory approvals including antitrust clearance.

Buyer: Teledyne Technologies — a U.S. technology company providing sophisticated instrumentation, digital imaging products, aerospace and defense electronics, and engineered systems. Headquartered in Thousand Oaks, California.

Target: Varex Imaging Corporation — a leading manufacturer of X-ray imaging components, including X-ray tubes, digital flat panel detectors, photon-counting detectors, high-voltage connectors, and imaging software. Headquartered in Salt Lake City, Utah.

Transaction Value: Approximately $1.1 billion.

Per Share Price: $18.90 in cash.

Expected Closing: Early 2027.

Teledyne's existing portfolio includes image sensors, cameras, and electronic systems used in scientific, industrial, and defense applications. Varex manufactures the X-ray sources (tubes) and detectors that are the core components of X-ray imaging systems used in medical diagnosis, oncology treatment, industrial inspection, vehicle scanning, and security screening.

The combination creates a more complete imaging technology stack. Teledyne gains direct access to the X-ray source and detector market — components that are upstream of the camera and sensor systems it already makes. The parties describe their product portfolios as largely complementary with limited overlap, which is the standard framing for a transaction intended to demonstrate a favorable antitrust profile.

Varex's customer base spans hospitals and diagnostic imaging centers (medical X-ray), airports and border crossings (security screening), manufacturing facilities (industrial inspection), and oncology treatment centers (linear accelerators). This breadth means the transaction is not purely a medical device deal — it also has significant industrial and security dimensions.

The parties' claim of minimal product overlap should be verified on a product-by-product basis during the regulatory review process. Teledyne's imaging sensors and Varex's X-ray detectors may compete in certain niche applications — particularly in scientific and industrial imaging — where both companies supply components to the same system integrators or end customers.

Counsel should map the competitive overlap at the component level, not just at the business segment level, to identify any markets where the combined entity would have a dominant position. The expected early 2027 closing timeline suggests the parties anticipate a standard antitrust review rather than an extended investigation.

Both Teledyne and Varex have significant defense and security applications in their product portfolios. Teledyne's aerospace and defense electronics are subject to U.S. export control regulations under the Export Administration Regulations (EAR) and the International Traffic in Arms Regulations (ITAR). Varex's security screening products — used in vehicle and cargo scanning at borders and ports — may also be subject to export control restrictions.

Due diligence must include a comprehensive export control compliance review covering: classification of all products under EAR/ITAR; existing export licenses and their transferability; any pending or historical export control violations; and the impact of the transaction on existing license agreements with foreign customers.

Varex's X-ray tubes and detectors used in medical applications are regulated medical devices. Due diligence must cover: FDA 510(k) clearances and PMA approvals for medical products; quality management system compliance (ISO 13485); product recall history; and pending or threatened regulatory actions. The integration of Varex's medical device quality systems into Teledyne's broader quality framework will require careful planning.

X-ray tube and detector technology involves significant proprietary know-how and patent portfolios. The due diligence should map Varex's patent portfolio, identify any cross-licensing arrangements with competitors, and assess the freedom-to-operate position of the combined entity in key technology areas.

Varex supplies X-ray components to major medical imaging OEMs (including Siemens Healthineers, Philips, and GE HealthCare) and industrial and security system integrators. These OEM supply agreements likely contain change-of-control provisions that may require customer consent or notification. Identifying and managing these provisions is a critical pre-closing workstream.

Varex has long-term supply agreements with key customers. These agreements should be reviewed for change-of-control provisions, minimum volume commitments, pricing mechanisms, and termination rights that could be triggered by the transaction.

The Teledyne–Varex transaction illustrates a recurring theme in defense and industrial technology M&A: the acquisition of component manufacturers to achieve vertical integration across the imaging or sensing stack. By owning both the sensor/camera layer (Teledyne) and the X-ray source/detector layer (Varex), the combined entity can offer more complete solutions to system integrators and end customers.

The transaction also highlights the complexity of deals that span multiple regulated industries simultaneously. A single transaction involving medical devices, defense electronics, and security technology requires parallel due diligence workstreams across FDA compliance, export controls, and antitrust — each with its own regulatory timeline and risk profile.

ULF New York provides legal advisory services on cross-border M&A, technology transactions, and regulatory compliance. This article is for informational purposes only and does not constitute legal advice.